Nav: Home

Making milestones against non-small cell lung cancer

January 24, 2018

New Haven, Conn. -- Hard to detect in its early stages and hard to treat as it advances, lung cancer is the leading cause of cancer mortality around the world, with an estimated 1.6 million deaths each year. New treatments, however, are bettering the odds for people with non-small cell lung cancer (NSCLC), which makes up about 85 percent of lung cancer cases.

"Progress has been enormous in the past 20 years," said Roy Herbst, M.D., Ph.D., chief of Medical Oncology at Yale Cancer Center and professor of Medicine and Pharmacology at Yale School of Medicine.

Traditionally, NSCLC has been treated by surgery followed by chemotherapy or radiation or both. "Options for treatments have improved in recent years with the advent of two classes of drugs, molecularly targeted therapies and more recently immunotherapies," said Herbst, co-lead author on a paper reviewing advances in NSCLC treatment published in the journal Nature. (Co-lead authors include: Daniel Morgensztern, M.D., associate professor of Medical Oncology at Washington University, and Chris Boshoff, senior vice president for Global Product Development for Oncology, Pfizer Inc., and adjunct professor, Yale School of Medicine.)

Molecularly targeted drugs aim to attack tumor cells that have mutated genes such as EGFR that can drive cancer. The Food & Drug Administration (FDA) gave its first approval for an EGFR inhibitor for NSCLC in 2004, and about a quarter of NSCLC patients now can be treated with various targeted drugs. Research is underway at Yale and many other Institutions to discover additional molecular targets. However, patients eventually develop resistance to these medicines, Herbst said.

Another wave of treatment options began to arrive in 2015 when the FDA approved the first "immune checkpoint blocker" for patients with advanced NSCLC. These immunotherapies clog up mechanisms that prevent the body's immune T cells from attacking tumors, by inhibiting a protein called PD-1 on the surface of T cells or its partner protein PD-L1 on tumor cells. Patients whose tumors show high levels of PD-L1 are generally the best candidates to benefit from such immunotherapies.

To date, immune checkpoint blockers work well for about one-fifth of NSCLC patients. "However, we've seen that although many tumors express PD-L1, many don't, and PD-L1 inhibition won't work for those," said Herbst. "Even among tumors that have high PD-L1 expression, many don't have any T cells in the tumor microenvironment, so that doesn't work either. We need to figure out how we're going to 'warm up' tumors and make them more sensitive to these different therapies." Additionally, as with targeted therapies, most tumors become resistant to immunotherapies over time.

Novel immunotherapies addressing other components of the immune system will be critical to overcome these challenges, Herbst suggested. Another key will be to combine immunotherapies, or to pair them up with chemotherapy, targeted therapy, medicines that suppress the growth of blood vessels, or other forms of cancer treatments.

"We need to move the personalized approach that we've used for targeted therapy to immunotherapy, matching the right patient to the right medicine at the right time," Herbst emphasized.

Other research efforts are creating new approaches to detect lung cancer and track it as it evolves in each patient. Last year, the FDA approved a "liquid biopsy" test for NSCLC that can find certain types of EGFR mutations by sequencing fragments of tumor DNA that circulate in the blood. More advanced tests of this "circulating free tumor DNA" are being developed to support individualized lung cancer treatment. "A liquid biopsy lets you see things in real time, and you can do multiple biopsies because they are less invasive for the patient," Herbst said. "Liquid biopsies are not quite as sensitive as a tumor biopsy, but some evidence suggests that they might actually give a more realistic view of the disease throughout the entire body."

Clinical research in NSCLC is being accelerated by innovative large clinical studies, such as the Lung Master Protocol (Lung-MAP) trial, which has enrolled more than 1400 patients to test a host of targeted drug candidates among previously treated patients with squamous cell lung cancer. Lung-MAP is now extending its scope to test combinations of targeted medicines and immunotherapies.

Herbst directs Yale's Specialized Program of Research Excellence (SPORE) for lung cancer, one of three lung cancer SPOREs funded by the National Cancer Institute. The program brings together experts in oncology, immunobiology, pharmacology, molecular biology, pathology, epidemiology and addiction science to attack the disease. "We aim to bring results from the lab to the clinic and back again," he said.

"Overall, we're seeing unprecedented benefits for people with NSCLC, but it's a very tough disease," Herbst summed up. "We're still only helping 30 or 35 percent of patients. Our research has to remain novel and innovative. We still have a lot of work to do."
-end-
About Yale Cancer Center

Yale Cancer Center (YCC) is one of only 49 National Cancer Institute (NCI-designated comprehensive cancer) centers in the nation and the only such center in southern New England. Comprehensive cancer centers play a vital role in the advancement of the NCI's goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.

Yale University

Related Lung Cancer Articles:

AI helps to fight against lung cancer
Lung cancer has been the leading cause of cancer-related deaths in 2015 in United States.
Free lung-cancer screening in the Augusta area finds more than double the cancer rate of previous screenings
The first year of free lung cancer screening in the Augusta, Ga., area found more than double the rate seen in a previous large, national study as well as a Massachusetts-based screening for this No.
Antioxidants and lung cancer risk
An epidemiological study published in Frontiers in Oncology suggests that a diet high in carotenoids and vitamin C may protect against lung cancer.
Lung cancer may go undetected in kidney cancer patients
Could lung cancer be hiding in kidney cancer patients? Researchers with the Harold C.
Hitgen and Cancer Research UK's Manchester Institute enter license agreement in lung cancer
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.
Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Huntsman Cancer Institute research holds promise for personalized lung cancer treatments
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another.
High levels of estrogen in lung tissue related to lung cancer in postmenopausal women
Researchers from Kumamoto University, Japan have found that postmenopausal women with multicentric adenocarcinoma of the lung have a higher concentration of estrogen in non-cancerous areas of the peripheral lung than similar women diagnosed with single tumor lung cancer.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Pericardial window operation less efficient in cases of lung cancer than any other cancer
Pericardial window operation, a procedure, where abnormal quantity of malignant fluid, surrounding the heart, is drained into the neighbouring chest cavity, is commonly applied to patients diagnosed with cancer.

Related Lung Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".